The development of BRAFTOVI is a testament to our commitment in advancing cancer care, and its inclusion in the FAST program is a validation of whats possible when industry, government, and other healthcare stakeholders collaborate to put patients first. Read more here: To view or add a comment, sign in We are living through a quiet revolution in oncology and most people haven't noticed yet
Moreover, a substantial methodological heterogeneity, including inconsistent protocols, lack of blinding, and unclear randomisation, limits the robustness of the conclusions
Oxidative stress enzymes are required for DAF-16-mediated immunity due to generation of reactive oxygen species by Caenorhabditis elegans
To address this, researchers are investigating intermittent or tissue-targeted ferroptosis inhibition, aiming to preserve physiological iron/ROS functions
Brenipatide side effects: what is actually known There is no published brenipatide side-effect list yet, because its Phase 3 alcohol-use-disorder trials, RENEW-ALC-1 and RENEW-ALC-2, do not report until 2027
